What is the latest ADVENZYMES stock price?
The latest stored price for ADVENZYMES is Rs 287.80 as of 2026-09-18.
gimli
ADVENZYMES stock AI analysis
ADVENZYMES Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
ADVANCED ENZYME TECH LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available ADVENZYMES price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹287.80
1W return
-5.13%
1M return
-5.02%
3M return
-22.92%
6M return
+2.09%
1Y return
-15.37%
Market cap
₹3,222.68 cr
PE
21.32
PB
1.91
ROE
+9.59%
ROCE
+11.14%
RSI
36.72
Turnover
₹7.00 cr
Why it can matter in screens
- Momentum: ADVENZYMES is below 50DMA, below 200DMA; RSI is 36.72.
- Returns: 1D -0.10%, 1W -5.13%, 1M -5.02%, 3M -22.92%, 1Y -15.37%.
- Trend levels: 52W high ₹395.75, 52W low ₹282.05, off high -27.28%.
- Liquidity: latest turnover is ₹7.00 cr; volume vs 20D is +1.13%.
- Valuation/profitability: PE 21.32, PB 1.91, ROE +9.59%, ROCE +11.14%.
- Growth: 3Y sales CAGR +11.33%, 3Y profit CAGR +16.89%.
Quick Answers
Is ADVENZYMES above its 50DMA and 200DMA?
ADVENZYMES is below 50DMA, below 200DMA. The latest 50DMA is 307.31 and the latest 200DMA is 314.01.
What are ADVENZYMES PE, ROE and ROCE?
ADVENZYMES has PE 21.32, ROE +9.59%, and ROCE +11.14% in Gimli's latest available snapshot.
How has ADVENZYMES performed recently?
ADVENZYMES has returned -5.02% over 1 month, -22.92% over 3 months, and -15.37% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 118.15 cr | 32.70 cr | 22.35 cr | 1.99 |
| 2026-03-31 | 203.37 cr | 70.57 cr | 42.96 cr | 3.84 |
| 2025-12-31 | 171.95 cr | 69.06 cr | 42.50 cr | 3.80 |
| 2025-09-30 | 184.53 cr | 70.34 cr | 43.33 cr | 3.87 |
| 2025-06-30 | 185.91 cr | 65.28 cr | 39.93 cr | 3.57 |
| 2025-03-31 | 167.18 cr | 54.35 cr | 26.48 cr | 2.37 |
| 2024-12-31 | 169.11 cr | 62.94 cr | 37.65 cr | 3.36 |
| 2024-09-30 | 146.09 cr | 52.03 cr | n/a | 2.94 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 745.76 cr | 275.26 cr | 168.72 cr | 11.76 |
| 2025-03-31 | 636.91 cr | 227.48 cr | 131.12 cr | 11.72 |
| 2024-03-31 | 623.48 cr | 225.99 cr | 133.31 cr | 11.92 |
| 2023-03-31 | 540.38 cr | 177.84 cr | 105.64 cr | 9.45 |
| 2022-03-31 | 281.88 cr | 207.84 cr | 54.51 cr | 10.70 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 1,838.76 cr | 108.75 cr | 32.01 cr | 1,683.12 cr |
| 2025-03-31 | 1,621.35 cr | 94.22 cr | 39.35 cr | 1,468.67 cr |
| 2024-03-31 | 1,535.46 cr | 113.75 cr | 47.31 cr | 1,371.08 cr |
| 2023-03-31 | 1,421.85 cr | 96.42 cr | 33.50 cr | 1,284.17 cr |
| 2022-03-31 | 1,267.61 cr | 267.36 cr | 34.73 cr | 1,140.39 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 156.78 cr | 104.40 cr | n/a |
| 2025-03-31 | 142.50 cr | 107.72 cr | n/a |
| 2024-03-31 | 141.37 cr | 94.06 cr | n/a |
| 2023-03-31 | 140.36 cr | 102.18 cr | n/a |
| 2022-03-31 | 122.29 cr | 94.11 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +43.24% | +26.71% | +4.78% | +1.82% | +25.27% | +0.00% |
| 2026-03-31 | +43.26% | +25.49% | +5.41% | +1.93% | +25.84% | +0.00% |
| 2025-12-31 | +43.04% | +25.86% | +5.51% | +2.16% | +25.59% | +0.00% |
| 2025-09-30 | +43.07% | +25.41% | +6.41% | +3.24% | +25.10% | +0.00% |
| 2025-06-30 | +43.08% | +23.46% | +8.45% | +5.46% | +25.02% | +0.00% |
| 2025-03-31 | +43.08% | +11.90% | +8.19% | +5.36% | +36.83% | +0.00% |
| 2024-12-31 | +42.93% | +12.58% | +8.18% | +5.57% | +36.32% | +0.00% |
| 2024-09-30 | +42.95% | +12.63% | +8.02% | +5.57% | +36.41% | +0.00% |
| 2024-06-30 | +43.02% | +12.03% | +8.08% | +5.82% | +36.87% | +0.00% |
| 2024-03-31 | +43.49% | +23.01% | +7.56% | +5.50% | +25.94% | +0.00% |
| 2023-12-31 | +43.62% | +22.54% | +6.98% | +5.42% | +26.86% | +0.00% |
| 2023-09-30 | +45.92% | +22.27% | +6.49% | +5.84% | +25.33% | +0.00% |
| 2023-06-30 | +46.52% | +21.90% | +7.59% | +7.08% | +24.00% | +0.00% |
| 2023-03-31 | +49.87% | +21.86% | +5.73% | +5.29% | +22.54% | +0.00% |
| 2022-12-31 | +49.87% | +21.74% | +5.64% | +5.25% | +22.75% | +0.00% |
| 2022-09-30 | +49.87% | +21.68% | +5.61% | +5.36% | +22.84% | n/a |
| 2022-06-30 | +52.70% | +0.00% | +24.98% | n/a | n/a | +0.00% |
| 2022-03-31 | +52.70% | +0.00% | +24.91% | n/a | n/a | +0.00% |
| 2021-12-31 | +52.71% | +0.00% | +25.38% | n/a | n/a | +0.00% |
| 2021-09-30 | +52.55% | +0.00% | +24.93% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze ADVANCED ENZYME TECH with valuation, momentum and industry peers
- Compare ADVENZYMES with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare ADVENZYMES with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.